Drugs / gp100:209-217(210M)
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01176461 | Aug 2010 → Dec 2016 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1 | NCT00028431 | Aug 2001 → Jan 2003 | melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00357461 | May 2006 → ? | cutaneous melanoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 2 | NCT00273910 | Jan 2006 → May 2010 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00005949 | Mar 2001 → Mar 2006 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001832 | Aug 1999 → May 2010 | melanoma, metastatic neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003895 | Apr 1999 → Sep 2013 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00019682 | Dec 1999 → May 2011 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100:209-217(210M) | “Patients were randomly assigned to receive interleukin-2 alone (720,000 IU per kilogram of body weight per dose) or gp100:209-217(210M) plus incomplete Freund's adjuvant...” PMID 21631324 ↗ Jun 20117“The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35 (27L) which are emulsified with IFA.” NCT00028431 ↗ |
| Action | Deplete | “Vaccines made from gp100 peptides may help the body build an effective immune response to kill tumor cells.” NCT00357461 ↗ |
| Modality | Peptide | “gp100:209-217(210M) peptide” NCT00001832 ↗ |
| Route | Subcutaneous | “gp100:209-217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh)” NCT00001832 ↗ |